Plus   Neg

Cannabis Stocks Regaining Strength


Shares of major cannabis companies are recovering from the extended losses they suffered on Monday following the U.S. Food and Drug Administration held its first-ever public hearing on cannabis and cannabidiol or CBD.

Shares of Tilray Inc. (TLRY) and Aurora Cannabis Inc. (ACB) are gaining more than 4 percent each, while those of Cronos Group Inc. (CRON) and Canopy Growth Corp. (CGC) are rising more than 3 percent each.

The FDA hearing did not result in any final decision, but it showed the conflicting views people had on the subject. While some people called for strict oversight of the booming CBD industry, companies involved in the industry lobbied for looser regulation.

According to acting FDA Commissioner Ned Sharpless, the regulator still does not know how safe the cannabis compound is for humans, despite its "widespread use in foods and dietary supplements."

More than 100 speakers, including manufacturers, researchers, advocates and opponents, offered divergent views on the subject on Friday. The divergent views underscored the need for an FDA decision as soon as possible so as to eliminate the confusion created due to uncertain regulatory atmosphere.

Friday's hearing is seen as just the first step in a process that could take years for the FDA to establish a legal path for marketing CBD products.

Major cannabis companies like Aurora Cannabis Inc., Canopy Growth Corp., Cronos Group Inc. and Tilray Inc. all saw their stocks fall sharply on Friday and also witnessed the extension of loss on Monday.

The FDA hearing to assess the safety and efficacy of CBD products in food and drinks came after hemp was legalized in the 2018 Farm Bill, which has resulted in CBD derived from hemp being legal in the U.S.

CBD is a naturally-occurring cannabinoid constituent of cannabis. It is a chemical in the marijuana plant often used for medicinal purposes, and does not have the intoxicating effects like those caused by tetrahydrocannabinol or THC.

As CBD is believed to relieve or ease symptoms related to health problems, CBD-infused products such as beer, iced tea, jelly beans and ice cream are flooding the market. The CBD industry is expected to be a $20 billion industry by 2022.

However, the FDA prohibits adding CBD to food and beverages as it views CBD as a drug.

Last June, the FDA for the first time approved a cannabis plant-derived, CBD-based drug, Epidiolex. The drug was approved to treat Dravet Syndrome and Lennox-Gastaut syndrome, two severe and rare forms of epilepsy.

But due to the strong public interest in CBD as a wellness aid, the FDA is seeking to establish a legal path to market for CBD products.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The U.S. Food and Drug Administration on Tuesday unveiled a new international collaboration for simultaneous review and approval of cancer drugs along with the agency's Australian and Canadian counterparts. The simultaneous approval of cancer therapies by the three regulators is intended to accelerate the process of making these new treatments available to patients around the world. Humanscale Corp. recalled about 24,900 units of QuickStand Lite workstations for concerns of injury hazard. These include about 2,200 units sold in Canada. The recalled workstation's arm can break and cause the workstation to fall, posing a risk of injury. The company has already received 52 reports of the arm breaking, including 12 reports of minor injuries. Facebook has revealed more details on the structure of an independent "oversight board" that will make final decisions about what posts stay up or come down, even if the company disagrees. The new "Oversight Board" will govern appeals from both Facebook and its users.
Follow RTT